Clinical and Translational Oncology

, Volume 14, Issue 12, pp 911–922

Clinical importance of phosphatase of regenerating liver-3 expression in breast cancer

Authors

    • Department of Medical OncologyDr. Lutfi Kirdar Kartal Education and Research Hospital
    • Selimiye Mah. Sair Nesimi Sok
  • Ahmet Bilici
    • Department of Medical OncologyDr. Lutfi Kirdar Kartal Education and Research Hospital
  • Nagehan Ozdemir Barisik
    • Department of PathologyDr. Lutfi Kirdar Kartal Education and Research Hospital
  • Mehmet Aliustaoglu
    • Department of Medical OncologyDr. Lutfi Kirdar Kartal Education and Research Hospital
  • Fugen Aker Vardar
    • Department of PathologyHaydarpasa Numune Education and Research Hospital
  • Burcak Erkol Yilmaz
    • Department of Medical OncologyDr. Lutfi Kirdar Kartal Education and Research Hospital
  • Mesut Seker
    • Department of Medical OncologyDr. Lutfi Kirdar Kartal Education and Research Hospital
  • Mahmut Gumus
    • Department of Medical OncologyDr. Lutfi Kirdar Kartal Education and Research Hospital
Research Article

DOI: 10.1007/s12094-012-0880-5

Cite this article as:
Ustaalioglu, B.B.O., Bilici, A., Barisik, N.O. et al. Clin Transl Oncol (2012) 14: 911. doi:10.1007/s12094-012-0880-5

Abstract

Background

Several biomarkers have been previously studied for breast cancer to define risk of recurrence and metastasis. Phosphatase of regenerating liver-3 (PRL-3) is one of them. High PRL-3 expression has been found to be correlated with axillary lymph node metastasis and survival in breast cancer. Herein, we evaluated the prognostic significance of PRL-3 expression and the relationship between PRL-3 and other clinicopathological factors.

Methods

PRL-3 expression was analyzed immunohistochemically in 122 invasive breast cancer tissues. We evaluated the correlation between PRL-3 and other clinicopathological factors by χ² test. Kaplan–Meier test and log rank method were used to define prognostic importance of PRL-3 expression.

Results

Of 122 breast cancer tumor samples, 46 (37.7 %) were negative while 76 (62.3 %) were positive in respect to PRL-3 expression. There was significant correlation between PRL-3 expression and other clinicopathological factors, such as histology, lymphovascular invasion (LVI), necrosis, progesterone receptor (PR) status, and the presence of triple negative disease. Tumors with LVI and necrosis had more positive PRL-3 expression compared to tumors without LVI or necrosis (P = 0.05 and 0.03, respectively). Triple negative and cerb-B overexpressed breast cancers were found to be more positive PRL-3 expression than hormone receptor positive with cerb-B negative groups (luminal A) (P = 0.02).We could not find any relationship between PRL-3 expression and overall survival (OS) or disease-free survival (DFS) (P > 0.05).

Conclusion

Although PRL-3 expression was related to LVI or necrosis which is important for tumor invasiveness, we could not find that PRL-3 as an important prognostic factor in breast cancer patients. In addition, triple negative and cerb-B overexpressed tumors, which had worse prognosis compared to hormone receptor positive without cerb-B expressed group, associated with also PRL-3 positivity more than PRL-3 negative group.

Keywords

Breast cancer PRL-3 Prognosis Molecular classification

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2012